Skip to main content

Advertisement

Log in

The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival

  • Research Paper
  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

We aimed to define the clinicopathologic characteristics of breast cancer (BC) patients with brain metastasis (BM) and to investigate the effect of these parameters on survival. Seventy-nine patients diagnosed with BC and symptomatic BM between 1995 and 2011 were retrospectively evaluated. The relationship between clinicopathological features and outcome was investigated. Triple negative patients had the shortest overall survival (OS) while HR(+)HER2(−) patients had the longest (48.2  vs 88.2 months, 95 % CI; p = 0.33). Multivariate analysis demonstrated that luminal A subtype was the strongest positive predictor of prolonged OS (HR 0.48, 95 % CI 0.28–0.84; p = 0.01), while poor performance status (PS) (ECOG 3–4) at BM was the strongest predictor of shortened OS (HR 1.92, 95 % CI 1.21–3.06; p = 0.006). The patients with early-stage BC at diagnosis had BM later than the advanced-staged patients (47 months for Stage I–II disease, 23.2 months for Stage III–IV disease, 95 % CI; p = 0.002). Median survival after BM was 10.2 months (6.4–14 months, 95 % CI). The patients with liver or skin metastases had significantly shorter survival than the patients with only BM (4.8 vs 17 months, p < 0.001 for liver and 4.8 vs 11.1 months, p = 0.04 for skin). Multivariate analysis demonstrated that regardless of the BC subtype, lack of systemic therapy, and liver involvement were independent factors associated with increased risk of death (HR 4, 95 % CI 1.7–9.1; p = 0.001 and HR 2.2, 95 % CI 1.05–4.9; p = 0.036 respectively). Clinical outcome after BM mostly depends on the ECOG PS and the fact that whether the patient received systemic therapy or not. Systemic therapy prolongs survival especially in HER2 positive patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61(4):212

    Article  PubMed  Google Scholar 

  2. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22(14):2865

    Article  PubMed  Google Scholar 

  3. Tsukada Y, Fouad A, Pickren JW, Lane WW (1983) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. Cancer 52(12):2349

    Article  PubMed  CAS  Google Scholar 

  4. Lin NU, Winer EP (2007) Brain metastases: the HER2 paradigm. Clin Cancer Res 13(6):1648

    Article  PubMed  CAS  Google Scholar 

  5. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP (2008) Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 113(10):2638

    Article  PubMed  Google Scholar 

  6. Yerushalmi R, Woods R, Kennecke H, Speers C, Knowling M, Gelmon K (2010) Patterns of relapse in breast cancer: changes over time. Breast Cancer Res Treat 120(3):753

    Article  PubMed  CAS  Google Scholar 

  7. Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, Tudor IC, Wang LI, Brammer MG, Shing M, Yood MU, Yardley DA (2011) Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 17(14):4834

    Article  PubMed  CAS  Google Scholar 

  8. Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW (2008) Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 112(11):2359

    Article  PubMed  CAS  Google Scholar 

  9. Dawood S, Broglio K, Esteva FJ, Yang W, Kau SW, Islam R, Albarracin C, Yu TK, Green M, Hortobagyi GN, Gonzalez-Angulo AM (2009) Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 20(4):621

    Article  PubMed  CAS  Google Scholar 

  10. AJCC (2010) Cancer staging manual, 7th edn. Springer, Chicago

    Google Scholar 

  11. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer:I. The value of histologic grade in breast cancer:expreience from a large study with long-term follow-up. Histopathology 19:403–410

    Article  PubMed  CAS  Google Scholar 

  12. Fitzgibbons PL, Page DL, Weaver D et al (2000) Prognostic factors in breast cancer. College of American pathologists consensus statement 1999. Arch Pathol Lab Med 124:966–978

    PubMed  CAS  Google Scholar 

  13. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655

    Article  PubMed  CAS  Google Scholar 

  14. Boogerd W (1996) Central nervous system metastasis in breast cancer. Radiother Oncol 40:5–22

    Article  PubMed  CAS  Google Scholar 

  15. Lee SS, Ahn J, Kim MK, Sym SJ, Gong G, Ahn SD, Kim S, Kim WK (2008) Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res Treat 111:523–530

    Article  PubMed  Google Scholar 

  16. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406:747–752

    Article  PubMed  CAS  Google Scholar 

  17. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423

    Article  PubMed  CAS  Google Scholar 

  18. Prat A, Baselga J (2008) The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with coexpression of HER2. Nat Clin Pract Oncol 5:531–542

    Article  PubMed  CAS  Google Scholar 

  19. Park YH, Lee S, Cho EY, Choi YL, Lee JE, Nam SJ, Yang J-H, Ahn JS, Im Y-H (2010) Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status. Cancer Chemother Pharmacol 66:507–516

    Article  PubMed  CAS  Google Scholar 

  20. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW (2008) Subtypes of breast cancer show preferential site of relapse. Cancer Res 68:3108–3114

    Article  PubMed  CAS  Google Scholar 

  21. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ (2003) The Her-2/neu gene and protein in breast cancer. Oncologist 8:307–325

    Article  PubMed  CAS  Google Scholar 

  22. Gori S, Rimondini S, De Angelis V, Colozza M, Bisagni G, Moretti G, Sidoni A, Basurto C, Aristei C, Anastasi P, Crino L (2007) Central nervous system metastases in HER2-positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist 12:766–773

    Article  PubMed  Google Scholar 

  23. Smid M, Wang Y, Klijn JG, Sieuwerts AM, Zhang Y, Atkins D, Martens JW, Foekens JA (2006) Genes associated with breast cancer metastatic to bone. J Clin Oncol 24:2261–2267

    Article  PubMed  CAS  Google Scholar 

  24. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537–549

    Article  PubMed  CAS  Google Scholar 

  25. Deckers M, van Dinther M, Buijs J, Que I, Löwik C, van der Pluijm G, ten Dijke P (2006) The tumor suppressor Smad4 is required for transforming growth factor β-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res 66:2202–2209

    Article  PubMed  CAS  Google Scholar 

  26. Niwinska A, Murawska M, Pogoda K (2010) Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 21:942–948

    Article  PubMed  CAS  Google Scholar 

  27. Niwinska A, Olszewski W, Murawska M, Pogoda K (2011) Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes. J Neurooncol 105:547–553

    Article  PubMed  CAS  Google Scholar 

  28. Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM (2012) Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. Cancer. doi:10.1002/cncr.27434

    Google Scholar 

  29. Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R (2006) Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 107(4):696–704

    Article  PubMed  Google Scholar 

  30. Kwon HC, Oh SY, Kim SH, Lee S, Kwon KA, Choi YJ, Cho GJ, Kim YS, Lee M, Lee JH, Kim DC, Lee HS, Cho SH, Kim HJ (2010) Clinical outcomes and breast cancer subtypes in patients with brain metastases. Onkologie 33(4):146–152

    Article  PubMed  Google Scholar 

  31. Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, Traut A, du Bois A (2009) Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 45(16):2792–2798

    Article  PubMed  CAS  Google Scholar 

  32. Berghoff A, Bago-Horvath Z, De Vries C, Dubsky P, Pluschnig U, Rudas M, Rottenfusser A, Knauer M, Eiter H, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R (2012) Brain metastases free survival differs between breast cancer subtypes. Br J Cancer 106(3):440–446

    Article  PubMed  CAS  Google Scholar 

  33. Harputluoglu H, Dizdar O, Aksoy S, Kilickap S, Dede DS, Ozisik Y, Guler N, Barista I, Gullu I, Hayran M, Selek U, Cengiz M, Zorlu F, Tekuzman G, Altundag K (2008) Charactersitics of breast cancer patients with central nervous system metastases: a single-center experience. J Natl Med Assoc 100(5):521–526

    PubMed  Google Scholar 

  34. Kim HJ, Im SA, Keam B, Kim Y-J, Han S-W, Kim TM, Oh D-Y, Kim JH, Lee S-H, Chie EK, Han W, Kim D-W, Kim T-Y, Noh D-Y, Heo DS, Park IA, Bang Y-J, Ha SW (2012) Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. J Neurooncol 106:303–313

    Article  PubMed  Google Scholar 

  35. Altaha R, Crowell E, Hobbs G, Higa G, Abraham J (2005) Increased risk of brain metastases in patients with HER-2/neu-positive breast carcinoma. Cancer 103:442–443

    Article  PubMed  Google Scholar 

  36. Pinder M, Chang HY, Broglio KM et al. (2007) Trastuzumab treatment and brain metastases in HER2-positive metastatic breast cancer. In Poster 1018 Presented at the 43rd ASCO Annual Meeting, Chicago, (Abstr 1018)

  37. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V et al (2006) Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 15:219–225

    Article  PubMed  CAS  Google Scholar 

  38. Yau T, Swanton C, Chua S, Sue A, Walsh G, Rostom A, Johnston SR, O’Brien ME, Smith IE (2006) Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 45:196–201

    Article  PubMed  CAS  Google Scholar 

  39. Yardley DA, Kaufman PA, Mayer M, et al. (2007) RegistHER: patient characteristics and time course of central nervous system metastases in patients with HER2-positive metastatic breast cancer. In Poster 6049 Presented at the 30 th Annual San Antonio Breast Cancer Symposium, San Antonio, (Abstr 6049)

  40. Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P (2005) Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 16:1772–1777

    Article  PubMed  CAS  Google Scholar 

  41. Stemmler HJ, Heinemann V (2008) Central nervous system metastases in HER2-overexpressing metastatic breast cancer: a treatment challenge. Oncologist 13:739–750

    Article  PubMed  Google Scholar 

  42. Park YH, Park MJ, Ji SH, Yi SY, Lim DH, Nam DH, Lee J-I, Park W, Choi DH, Huh SJ, Ahn JS, Kang WK, Park K, Im Y-H (2009) Trastuzumab treatment improves brain metastases outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer 100(6):894–900

    Article  PubMed  CAS  Google Scholar 

  43. Anders CK, Deal AM, Miller CR, Khorram C, Meng H, Burrows E, Livasy C, Fritchie K, Ewend MG, Perou CM, Carey LA (2011) The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer 117(8):1602–1611

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lutfiye Demir.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tarhan, M.O., Demir, L., Somali, I. et al. The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival. Clin Exp Metastasis 30, 201–213 (2013). https://doi.org/10.1007/s10585-012-9528-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10585-012-9528-7

Keywords

Navigation